Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

TC BioPharm (NASDAQ: TCBP) has received $250,000 in non-dilutive funding from the G-Rex® Grant Program, a $20M initiative by ScaleReady, Wilson Wolf Manufacturing, and Bio-Techne Corporation to advance cell and gene-modified cell therapy development.

Portfolio Pulse from

November 12, 2024 | 2:45 pm

TC BioPharm has announced the signing of two non-binding letters of intent for acquisitions in cell therapy modalities outside its core TCB008. This move indicates a strategic expansion beyond its current focus.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:34 pm

LENZ Therapeutics shares rose 18% in pre-market trading following positive Phase 3 trial results in China. Other notable pre-market movers include Healthcare Triangle, Pixie Dust Technologies, and Jet.AI, with significant gains, while SMX and Upexi saw declines.

Portfolio Pulse from Avi Kapoor

October 28, 2024 | 10:32 am

TC BioPharm shares have resumed trading, which could indicate a resolution of previous issues that halted trading. Investors should monitor the stock for any further developments.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 1:51 pm

TC BioPharm's shares have been halted due to a significant upward movement, with the stock now up by 14.65%.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 1:47 pm

TC BioPharm (NASDAQ:TCBP) has refuted false social media claims about potential delisting from the Nasdaq. The company confirms it remains compliant with all listing requirements.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 1:46 pm

BioPharm shares rise following a collaboration with Dr. Carlos Maluquer de Motes to develop a Monkeypox treatment.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:48 pm

TC BioPharm (NASDAQ:TCBP) has entered a research collaboration with Dr. Carlos Maluquer de Motes to develop a treatment for Monkeypox. This partnership aims to leverage expertise in viral diseases and immune response.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:38 pm

In Tuesday's pre-market session, several health care stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also declined following its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also saw a decrease following its Q3 earnings report.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.